CAR-T therapy has transformed outcomes for patients with certain blood cancers. Yet across Europe, on average, only ~18% of eligible patients receive CAR-T therapy. The reality behind the numbers:Limited manufacturing capacity of centralized manufacturingComplex and uneven referral pathwaysReimbursement and funding barriersSignificant geographic disparities in accessImproving access requires more than bench-level innovation — it requires system-level solutions. At EASYGEN, we investigate a novel manufacturing process, working to address these barriers, starting with improving manufacturing scalability and timelines. On World Cancer Day, we believe in awareness and encourage that data should also lead to dialogue — and dialogue to action.💬 From your experience, what is currently the biggest barrier to CAR-T access in your setting? #WorldCancerDay #CARTtherapy #PatientAccess #Innovation #EASYGEN

‍This project has received funding from the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194710. The IHI JU receives support from the European Union’s Horizon Europe programme and industry partners. This project has received funding from the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194710. The IHI JU receives support from the European Union’s Horizon Europe programme and industry partners.